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Abstract
BACKGROUND—Serum prostate specific antigen (PSA) may be elevated in otherwise healthy
men; systemic inflammation has been associated with cancer. The study of systemic inflammatory
markers in men without clinical prostate disease, but with elevated PSA may characterize the
subgroup of men at higher risk for subsequent prostate cancer.
METHODS—We investigated the associations between systemic inflammatory markers and
serum PSA in 3,164 healthy men without prostatic disease, aged >40 years, from the 2001 to 2008
U.S. National Health and Nutrition Examination Survey (NHANES). Serum total PSA levels and
concentrations of serum C-reactive protein (CRP) and plasma fibrinogen, neutrophil count,
lymphocyte count, and platelet count were recorded. Neutrophil-lymphocyte ratio (NLR) ratio and
platelet-lymphocyte (PLR) ratio were calculated. PSA elevation was defined as levels equal or
greater than 4 ng/ml.
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RESULTS—Elevated serum PSA (194 men, 6.1% of the total), was significantly associated with
plasma fibrinogen (ORmultiv=1.88; 95% CI, 1.09–3.25), and NLR (ORmultiv=1.14; 95% CI, 1.03–
1.26), after adjustment for age, smoking, body mass index, education, race, co-morbidities, and
use of medications.
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CONCLUSIONS—Markers of systemic inflammation were associated with elevated PSA in men
without known prostatic disease. Future studies are needed to examine these markers’ relationship
with prostate cancer occurrence and progression.
Keywords
prostate cancer; systemic inflammation; screening; NHANES

INTRODUCTION
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Serum prostate-specific antigen (PSA) is the most widely used screening test for prostate
cancer (PC), though its use remains controversial. Although PSA has a good sensitivity, the
test suffers from low specificity due to the difficulty in distinguishing patients with PC
versus benign prostatic diseases [1]. Common urologic conditions, such as benign prostatic
hyperplasia (BPH), acute/chronic prostatitis, or urinary tract infection can be associated with
an elevated serum PSA. However, men with serum PSA levels ≥4.0 ng/ml are typically
considered to be at risk for occult PC, and are often referred for further evaluation and a
potential biopsy. As a result of the low specificity of PSA, a significant percentage of men
who undergo an invasive prostate biopsy do not have PC. Furthermore, an invasive biopsy
may miss cancer in some men, given that up to 20% of men will have PC on a repeat biopsy
[2] Other data show that men with a false positive PSA at screening are more likely to
develop PC during the follow-up [3]. The complexities of PC screening highlight the
potential clinical value of additional serum biomarker(s) which, among men with elevated
PSA, distinguishes those who may develop PC during the follow-up versus those with
benign prostate conditions.
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In an attempt to understand the biological meaning of a high PSA value, local and systemic
inflammation has been studied. Local prostate inflammation infiltrates have been found in
asymptomatic men with elevated PSA levels [4–8]; however, the evidence of an association
between histological inflammation and PC is inconsistent. In addition, local inflammation
was recently defined a non useful risk indicator in PC screening [9].
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Systemic inflammation may play a role in the development and progression of cancer;
epidemiologic evidence has linked PC to infectious agents, chronic and persistent infections,
and pro-inflammatory hormonal or dietary factors [10,11]. Elevated C-reactive protein
(CRP) and fibrinogen levels have been found to be associated with an increased risk of
developing colorectal and lung cancer [12,13]; markers such as CRP, platelet counts,
neutrophil counts, neutrophil-lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR)
were reported to be associated with progression and poorer prognosis for multiple different
cancers including lung, colorectal, pancreatic, ovarian, and PC [14–19]. However, there is
no information on how systemic inflammation links to PSA levels in asymptomatic men.
This is relevant, because if markers can be identified which track with PSA levels, it is
possible that they may correlate with PC risk, thus becoming a useful additional tool to
assess individual PC risk in men with elevated PSA.
To address this, we performed a cross-sectional study to test the association between serum
PSA and markers of systemic inflammation in men without clinical prostate diseases; we
Prostate. Author manuscript; available in PMC 2015 April 01.
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hypothesized that systemic inflammatory markers would be positively associated with
elevated serum PSA.

MATERIALS AND METHODS
Study Design and Population
The National Health and Nutrition Examination Survey (NHANES) is a population-based
survey that uses a complex, multistage design to collect health and nutritional information
from a nationally representative sample of non-institutionalized U.S. adults and children. In
this cross-sectional study, we aggregated all available data from 2001 to 2008 to examine
whether markers of systemic inflammation (CRP, fibrinogen, neutrophil count, platelet
count, lymphocyte count, and NLR and PLR) were associated with elevated serum PSA (≥4
ng/ml) in men, aged >40 years, with no known evidence of prostatic disease.
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Sample Selection
There were 6,832 men, aged >40 years, who participated in NHANES from 2001 to 2008.
Of these men, 1,180 were missing serum PSA data and were not screened for PC, therefore
were excluded; 2,488 men had various prostatic diseases including BPH, infection or
inflammation of the prostate, self reported history of malignancy including PC, self-reported
diagnosis of diabetes, taking 5-alpha-reductase inhibitors, and were therefore excluded from
the analyses, leaving 3,164 men (~46% of the original sample) included in the present
analysis. All study participants signed informed consent forms; and, the 2001–2008
NHANES was approved by the Research Ethics Review Board of the National Center for
Health Statistics.
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Data Collection
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Demographic information (age, race, marital status, and educational status), current and past
medical conditions, medication use (beta-blockers, statins, and nonsteroidal antiinflammatory drugs), and lifestyle behaviors (i.e., alcohol drinking and smoking) were
collected through questionnaires administered by trained interviewers. Meanwhile, medical
examinations were conducted and participants’ body mass index (BMI) (kg/m2) was
measured. Blood specimens were collected and laboratory tests were performed to examine
the following: serum total PSA levels (ng/ml), serum CRP levels (mg/dl), plasma fibrinogen
levels (g/L), neutrophil count (1,000 cells/µl), lymphocyte count (1,000 cells/µl), and platelet
count (1,000 cells/µl). NLR was calculated as neutrophil cell count divided by lymphocyte
cell count; and PLR was calculated as platelet count divided by lymphocyte cell count. Not
all laboratory tests were performed throughout the 2001–2008 NHANES time period; as a
result, sample size for the analysis of each marker was slightly different.
Laboratory Analysis
Latex-enhanced nephelometry was used to measure the quantification of high-sensitivity
CRP in serum [20]. Plasma fibrinogen was determined by using the Clauss clotting method
[21]. Complete blood count of platelets and white blood cells which include neutrophils and
lymphocytes were determined by using the Beckman Coulter method [22]. Total PSA levels
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in serum were determined using the Access Hybritech PSA assay (Beckman Coulter, Inc.)
[23].
Data Analysis
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Men were categorized as having either normal (<4 ng/ml) or elevated (≥4 ng/ml) serum
PSA; study characteristics were compared between the two PSA groups using a chi-square
test for categorical variables and a Student’s t-test for continuous variables. The geometric
mean and standard error were calculated for these markers of systemic inflammation due to
their skewed frequency distribution. Univariate, age-adjusted, and multivariable logistic
regression models were used to examine whether markers of systemic inflammation,
considered one at a time, were associated with elevated serum PSA by calculating the odds
ratios (OR) and 95% confidence intervals (CI). In these analyses, markers of systemic
inflammation (independent variables) were entered as a continuous variable in the regression
models. Multivariable logistic regression analyses that examined the relationship between
markers of systemic inflammation and elevated serum PSA were adjusted for the following
variables due to their possible influence on serum PSA: age (continuous), ever smoker (yes
or no), BMI (continuous), education (<high school, high school graduate, or >high school),
race (Black, White, or other), medications (beta blockers, statins, and nonsteroidal antiinflammatory drugs), and co-morbid conditions (heart disease, asthma, arthritis, chronic
bronchitis, and emphysema).
All data analyses used the appropriate survey sample weights to provide nationally
representative estimates. Statistical significance was determined at alpha level of 0.05. Data
analysis was conducted in SAS version 9.3 (SAS Institute, Cary, NC).
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RESULTS
Of the 3,164 study participants, there were 2,970 (93.9%) and 194 (6.1%) men who had a
normal and elevated serum PSA, respectively. On average, men with elevated PSA were
significantly older, less likely to report drinking alcohol, and had a significantly lower BMI
compared to men with normal PSA (Table I). Men with elevated PSA were also less
educated, more likely to take beta blockers and statin, and less likely to take NASIDs in
comparison to men with normal PSA; however, these differences were not statistically
significant (Table I).
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Men with elevated PSA had significantly higher geometric mean for serum CRP, plasma
fibrinogen, NLR, and PLR compared to men with normal PSA. Lymphocytes were
significantly lower in men with elevated PSA in comparison to men with normal PSA
(Table II).
In univariate logistic regression analyses, serum CRP levels (ORcrude=1.19; 95% CI. 1.06–
1.33), plasma fibrinogen levels (ORcrude=2.12; 95% CI, 1.56–2.87), and NLR
(ORcrude=1.34; 95% CI, 1.21–1.48) were significantly associated with elevated PSA (Table
III). When the analyses were age-adjusted, only plasma fibrinogen (ORage-adj=1.79; 95% CI,
1.29–2.50) and NLR (ORage-adj=1.15; 95% CI, 1.06–1.25) remained significantly associated
with elevated PSA. After further adjustment for smoking, BMI, education, race,
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medications, and co-morbidities, plasma fibrinogen (ORmultiv=1.88; 95% CI, 1.09–3.25),
and NLR (ORmultiv =1.14; 95% CI, 1.04–1.26) remained significantly and positively
associated with elevated PSA (Table III).

DISCUSSION
To our knowledge, the current study is the first to date to examine the relationship between
several systemic inflammatory markers and serum PSA levels among men without clinical
signs of prostate disease. A previous study [24], and has shown that CRP and PSA are
significantly associated. The study re-analyzed a data set from a clinical laboratory on an
unselected population of 300 men who underwent PSA screening, whose clinical profile was
unknown, thus some current and/or previously treated PC patients could have been included.
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We found that NLR and plasma fibrinogen were positively associated with elevated serum
PSA. These findings suggest that certain markers of systemic inflammation/immune system
activation are associated with an elevated serum PSA. Whether the high serum PSA levels
stem from unreported prostatic inflammation or BPH, undiagnosed PC, or some other source
is not known in the present study. Appropriately designed prospective studies are needed to
examine the source of the elevated PSA associated with increased markers of systemic
inflammation in healthy men. If the source is unrecognized PC, then this not only provides
further support for the link between inflammation and PC, but suggests that inflammatory
markers may be useful in PC detection.
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In this study, men with elevated serum PSA had a higher NLR in comparison to men with
normal PSA levels. Since NLR is believed to reflect the balance between innate
(neutrophils) and adaptive (lymphocytes) immune responses, its association with higher
serum PSA levels may indicate impairment in the adaptive host’s ability to control
inflammation. Studies have shown that elevated NLR is associated with increased
concentration of various pro-inflammatory cytokines in patients with recurrent liver cancer
and with colorectal cancer [15,25,26]. These pro-inflammatory cytokines may cause cellular
DNA damage that could increase cancer risk. Whether elevated NLR is associated with
increased concentration of pro-inflammatory cytokines in patients with elevated serum PSA
is not known in the present study. A study conducted among PC patients in Glasgow, United
Kingdom found a significant association between NLR and poor PC prognosis; however, the
relationship between NLR and PC risk was not examined [14]. Further studies that examine
interrelationships among NLR, pro-inflammatory cytokines, and PC risk are warranted.
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A positive relationship between plasma fibrinogen and elevated serum PSA was also
reported in the present study. Epidemiologic studies found higher fibrinogen levels in
patients with cancer compared to patients with benign tumors or healthy individuals [27,28].
Based on previous studies, fibrinogen has been found to be positively associated with
overall risk for smoking-associated cancers [13,29]; but its relationship with PC has been
less investigated. A recent study reported a null association between fibrinogen and PC risk
among Finnish men, aged ≥42 years [30]; however, the relationship between fibrinogen and
serum PSA was not examined in this or previous studies.
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In the present study, serum CRP levels were higher for men with elevated serum PSA
compared to men with normal serum PSA, although the association was not significant after
age and multivariable adjustments. This finding is consistent with a study that found serum
CRP positively associated with PSA in men (n=302), aged >35 years, who were referred for
PC screening, and in men with PSA levels of >2.5 ng/ml [24]. However a study conducted
among a random sample of men, aged 40–79 years, in the Olmstead County, Minnesota
cohort reported no association between elevated CRP levels and a rapid increase in PSA
levels [31]. Two studies, one conducted among a small sample of French men (n=156) [32],
the another within the Physicians’ Health Study, reported an association between PC and
serum CRP [33]. Whether men with elevated CRP and elevated PSA are at higher risk of PC
is a topic for future studies.
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The present study is unique because it used a large sample of the US general population with
PSA testing performed, where several biological markers were measured in a standardized
fashion. The database contains a wealth of individual clinical information on medical
history, hospital admissions, and pharmacological treatment, which allowed the exclusion of
subjects with history of PC or of other malignancy, as well as with conditions/medications
linked to inflammation and to PSA levels. Limitations of the study are the cross-sectional
nature of the survey which lacks follow-up information on the subjects interviewed, the
presence of missing data for parts of the sample, and the lack of details on some of the
demographic variables collected. Another limitation is that not all laboratory tests were
performed throughout the 2001–2008 time period, therefore the association of each systemic
marker with PSA was performed one at a time, and combined associations and interactions
could not be examined. Finally, the outcome was elevated PSA, not PC occurrence or PC
mortality as these data were not available in the present study. Despite these limitations, we
presented solid evidence that NLR and plasma fibrinogen are positively associated with
elevated serum PSA levels among a large sample of asymptomatic U.S. men. This is the first
study to comprehensively test inflammatory markers for their association with elevated
PSA.
Since an elevated PSA is indicative of increased PC risk [3], there is a need to further
understand if men with elevated inflammatory markers and elevated PSA are a distinct subgroup at increased risk of future PC during the follow-up.
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  Beta blockers

  Statin

  NSAIDs

  Intake of any of the 3 medications combined

23.3%

4.8%

13.9%

10.1%

62.2%

84.4%

46.2%

24.5%

29.3%

7.8%

17.9%

74.3%

27.9%

53.5%

18.6%

28.7 (0.13)

51.8 (0.20)

Mean (SD)
or percent

49

7

31

23

194

110/193

151/194

68

51

75

194

14

57

122

193

39

105

50

194

188

194

N

25.3%

3.6%

16.0%

11.9%

57.0%

77.8%

35.1%

26.3%

38.7%

7.3%

29.5%

63.2%

20.1%

54.1%

25.8%

27.6 (0.44)

63.6 (1.16)

Mean (SD)
or percent

PSA ≥ 4 ng/ml

0.56

0.07

0.42

0.08

0.4

0.03

0.07

0.14

0.2

0.02

<0.0001

P-value

N, number; PSA, prostate specific antigen; BMI, body mass index; NSAID, nonsteroidal anti-inflammatory drugs; SD, standard deviation.

2,970

Ever medication use

1,846/2,968

1,372

  More than high school

Ever smoker

728

  High school graduate

2,506/2,970

868

  Less than high school

Alcohol drinker

231
2,968

532

  Ever been married

Educational Status

2,205

  Currently married or live with partner

  Never been married

828
2,968

Marital status

  White

  Other

553
1,589

  Black

2,970

2,938

2,970

Race or ethnic origin

BMI

(kg/m2)

Age (years)

N

PSA < 4 ng/ml

Baseline Characteristics of Study Participants Stratified by Serum PSA Levels

Author Manuscript
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2,267
2,262
2,262

Neutrophil-Lymphocyte ratio

Platelet-lymphocyte ratio

124.82 (1.11)

2.00 (0.02)

245.53 (1.58)

1.97 (0.02)

3.94 (0.05)

3.41 (0.07)

0.17 (0.00)

Geometric mean (SE)

N, number; PSA, prostate specific antigen; and SE, standard error.

2,262

Platelets (1,000 cells/µl)

2,262

747

2,969

N

Lymphocytes (1,000 cells/µl)

Neutrophils (1,000 cells/µl)

Plasma Fibrinogen (g/L)

Serum C-reactive protein (mg/dl)

Variable

PSA < 4 ng/ml

145

145

146

145

145

48

194

N

136.90 (5.48)

2.32 (0.11)

241.48 (6.99)

1.76 (0.07)

4.09 (0.14)

3.93 (0.14)

0.22 (0.03)

Geometric mean (SE)

PSA : 4 ng/ml

0.03

0.002

0.55

0.007

0.36

0.0006

0.02

P-value

Comparison of Systemic Inflammatory Markers According to Serum PSA Levels

Author Manuscript
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Author Manuscript
145/2,262
145/2,262

Neutrophil-lymphocyte ratio

Platelet-lymphocyte ratio

1.01 (1.0–1.01)

1.34 (1.21–1.48)

1.0 (1.0–1.0)

1.03 (0.95–1.11)

1.06 (0.93–1.20)

2.12 (1.56–2.87)

1.19 (1.06–1.33)

Crude odds
ratio (95% CI)

1.0 (1.0–1.01)

1.15 (1.06–1.25)

1.0 (1.0–1.01)

1.03 (0.99–1.07)

1.03 (0.90–1.17)

1.79 (1.29–2.50)

1.11 (0.99–1.25)

Age-adjusted
odds ratio (95% CI)

140/2,232

140/2,232

41/2,237

140/2,232

140/2,232

45/729

187/2,933

Elevated/normal
PSA N of men

1.0 (1.0–1.01)

1.14 (1.04–1.26)

1.0 (1.0–1.01)

1.03 (0.99–1.07)

1.03 (0.91–1.17)

1.88 (1.09–3.25)

1.11 (0.98–1.27)

Multivariate model includes age (continuous), ever smoker (yes/no), body mass index (continuous), education (<high school, high school graduate, >high school), race (Black, White, other), medications
(beta blockers, statins, nonsteroidal anti-inflammatory drugs), and co-morbid conditions (heart disease, asthma, arthritis, chronic bronchitis, and emphysema).

a

N, number; PSA, prostate specific antigen; CI, confidence interval.

146/2,267

145/2,262

Lymphocytes (1,000 cells/µl)

Platelets (1,000 cells/µl)

145/2,262

48/747

194/2,969

Elevated/normal
PSA N of men

Neutrophils (1,000 cells/µl)

Plasma fibrinogen (g/L)

Serum C-reactive protein (mg/dl)

Variable

Multivariablea odds
ratio (95% CI)

Author Manuscript

Associations Between Systemic Inflammatory Markers and Serum PSA Levels

Author Manuscript
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